PeptideStack
5.2kquestions
20kanswers
220users

How does orforglipron at 24 mg weekly compare on cost per milligram across routes?

Asked 6 Jun 2026Modified 3 days agoViewed 7.2k times
21

Stated plainly: orforglipron · 24 mg.

I have worked this out and I would like someone to find the error, because I suspect there is one.

My working so far, for the record, is below, and I am fairly sure the error is in the unit conversion rather than the algebra.

Is my approach right even if my number is wrong?

cost-analysis
cost-analysis

Cost arithmetic done honestly: cost per milligram after dead-space loss, list versus net price, comparing a multi-dose vial to a fixed-dose pen,…

260 questions
vendor-comparison
vendor-comparison

Side-by-side comparison of suppliers on measurable axes - independently confirmed purity and content, lead time, cold-chain handling,…

388 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
shareeditfollowflag
IB
askedilaria_bertone33k386 Jun 2026
6Same question before my first order, and the small-order-then-test route worked. – fib4_reader 8 months ago
7Do you have a certificate in front of you, or are you asking before requesting one? – RP_C18 6 days ago
add a comment

5 Answers

Accepted answer first, then by votes
24

Accepted answer

24 mg a week is 1248 mg a year and 104 mg in an average month — put every route on that denominator before comparing anything. Cost per milligram is the only figure that survives the comparison, because the presentations differ: a licensed pen prices a dose, a compounding pharmacy prices a vial, and a research supplier prices a mass. Divide each one's twelve-month cost by 1248 mg and the three become the same number in the same unit. Then add what the cheapest route does not include — independent purity and content testing, the vials you discard, and the postage — because a route that needs testing to be trustworthy has that testing in its cost per milligram whether you account for it or not.

The relevant detail is that this is a spreadsheet question and doing it properly changes conclusions more often than people expect.

Carriage amortises across the order. Twenty-five pounds of carriage on one vial is £2.50/mg on a 10 mg vial; on ten vials it is £0.25/mg. That single term explains most of the case for larger, less frequent orders.

The full calculation: (unit price + carriage share + testing share) ÷ (nominal mg × measured content fraction × (1 − dead-space and wastage fraction)). Every term after the first is routinely omitted.

Syringe dead-space volumes are published per design, with fixed-needle insulin syringes under 5 microlitres and conventional luer designs at 35 microlitres or more.

Include carriage and testing as per-milligram terms. They dominate small orders.

shareimprove this answerflag
PH
answered · acceptedpetra_hovland35k3816 Jun 2026
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
20

Put another way, testing cost per milligram falls sharply with order size, which is the main argument against very small repeat orders.

Independent testing costs roughly the price of one to two vials at the services this community uses. On a two-vial order that is a fifty to a hundred per cent surcharge; on a twenty-vial order it is five per cent.

Dead-space loss is small with fixed-needle insulin syringes — a few microlitres per draw — and substantial with detachable-needle luer syringes at 35 to 100 microlitres. Across twenty draws that is up to two millilitres of solution.

Independent testing prices at the services this community uses are published and are stable enough to model.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Fixed-needle syringes save more peptide than most price differences do.

shareimprove this answerflag
DL
answeredDr_Otto_Lindqvist72k5828 Jun 2026
11

Start by listing every cost in the chain, since carriage, testing and wastage frequently exceed the difference in headline price.

Worked example. Supplier A: £60 for a 10 mg vial, content 96 per cent, so 9.6 mg for £60, or £6.25/mg before carriage. Supplier B: £52 for the same nominal vial, content 88 per cent, so 8.8 mg for £52, or £5.91/mg. B still wins here, but the gap has narrowed from thirteen per cent on the label to five per cent in reality.

Change one number and it reverses: if B assays at 82 per cent, that is 8.2 mg for £52, or £6.34/mg, and the cheaper vial is now the more expensive peptide.

Larger orders reduce cost per milligram and increase exposure to a single lot, which is a real trade rather than a free win.

Decide whether you are optimising cost or confidence before you build the model.

shareimprove this answerflag
LM
answeredlucia_marchetti19k2727 Jul 2026
7Thank you — the checklist format makes this actionable rather than merely correct. – tyndall_haze 6 months ago
8This should be linked from the help pages. – tare_weight 7 months ago
add a comment
8

Answer first: compare cost per milligram of measured peptide, not per milligram of label claim, because content varies enough to reverse a comparison.

Cost per milligram is the wrong metric entirely if you are optimising for confidence rather than price, and it is worth saying which one you are doing before you build the spreadsheet.

Carriage on international consignments scales sub-linearly with weight, which is the quantitative basis for order consolidation.

The caveat is that optimising cost per milligram optimises for the wrong thing if documentation and consistency are what you actually need.

Divide by measured content, not by label claim. That is the whole correction.

shareimprove this answerflag
TN
answeredtabular_nums71k4814 Jul 2026
8Worth adding that legal position and enforcement posture are different things. – syringe_ninety 9 months ago
add a comment
6

In practice, wastage from expired reconstituted vials is a real line item and nobody includes it.

Wastage from a reconstituted vial discarded at the end of its in-use period is a genuine cost, and it is a function of the diluent volume chosen at reconstitution rather than of anything the supplier did.

Published content assay results across the independent services show nominal and measured content differing by one to ten per cent, which is the term that makes label-price comparisons unreliable.

A spreadsheet built on label claim rather than measured content is precise about the wrong number.

Larger orders are cheaper per milligram and concentrate lot risk. Price both.

shareimprove this answerflag
EL
answeredesben_lykke84k1581 Jul 2026
5I have kept every invoice and declaration, which I gather is the useful habit. – low_dead_space 34 days ago
6Same experience here, different supplier. – Dr_Nadia_Farsi 3 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.